FumitoItoMDPhD, FACS

General Surgery • Los Angeles, CA

Breast, Melanoma, Surgical Oncology (Other than Breast)

Surgical Oncologist, University of Southern California

Join to view full profile

Dr. Ito is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ito's full profile

Already have an account?

Office
1450 Biggy St.
Los Angeles, CA 90033

Clinical Expertise

Melanoma and cutaneous malignancies, Breast cancer, Breast surgery, Surgical oncology (non-breast)

Education & Training

Shiga University of Medical ScienceClass of 1995

Certifications & Licensure

CA State Medical License 2021 - 2025
NY State Medical License 2008 - 2025
MI State Medical License 2010 - 2017
WI State Medical License 2007 - 2011
American Board of Surgery Surgery

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Start of enrollment: 2023 Jan 09
Recruiting
Phase 1

Publications & Presentations

PubMed

Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2024-10-23
2 citations
Generation, Transcriptomic States, and Clinical Relevance of CX3CR1+ CD8 T Cells in Melanoma.
Hirohito Ishigaki, Takayoshi Yamauchi, Mark D Long, Toshifumi Hoki, Yuta Yamamoto
Cancer Research Communications. 2024-07-01
4 citations
Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors.
Layla Shojaie, Jacob M Bogdanov, Helia Alavifard, Mahmoud G Mohamed, Aria Baktash
Cell Death & Disease. 2024-02-14

Press Mentions

USC Team IDs Biomarker for NSCLC Response to ChemoimmunotherapyMay 17th, 2023
Study Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
USC Research Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
Join now to see all

Grant Support

Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy AssayNational Cancer Institute (NCI)2022–2027
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors.National Cancer Institute (NCI)2021–2026

Committees

Co-Leader, USC Translational and Clinical Sciences (TACS) program

Other Languages

Japanese